Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - Wiley Online Library
A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
TA Leil, Y Feng, L Zhang, A Paccaly… - Clinical …, 2010 - pubmed.ncbi.nlm.nih.gov
A model-based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose.
TA Leil, Y Feng, L Zhang, A Paccaly… - Clinical …, 2010 - search.ebscohost.com
A model-based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
[引用][C] Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
TA Leil, Y Feng, L Zhang, A Paccaly, P Mohan… - Clinical Pharmacology …, 2010 - cir.nii.ac.jp
Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism:
Selection of Phase III Trial Dose | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Selection of Phase III Trial Dose | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
[PDF][PDF] Quantification of Apixaban's therapeutic Utility in prevention of Venous thromboembolism: selection of phase III trial Dose
TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - researchgate.net
TA Leil1, Y Feng1, L Zhang1, A Paccaly1, P Mohan2 and M Pfister1 a model-based
approach was used to integrate data from a phase ii study in order to provide a quantitative …
approach was used to integrate data from a phase ii study in order to provide a quantitative …
[引用][C] Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
TA LEIL, Y FENG, L ZHANG… - Clinical …, 2010 - pascal-francis.inist.fr
Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism:
Selection of Phase III Trial Dose CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Selection of Phase III Trial Dose CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[PDF][PDF] Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - academia.edu
TA Leil1, Y Feng1, L Zhang1, A Paccaly1, P Mohan2 and M Pfister1 a model-based
approach was used to integrate data from a phase ii study in order to provide a quantitative …
approach was used to integrate data from a phase ii study in order to provide a quantitative …
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose.
TA Leil, Y Feng, L Zhang, A Paccaly… - Clinical …, 2010 - europepmc.org
A model-based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
[PDF][PDF] Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose
TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - academia.edu
TA Leil1, Y Feng1, L Zhang1, A Paccaly1, P Mohan2 and M Pfister1 a model-based
approach was used to integrate data from a phase ii study in order to provide a quantitative …
approach was used to integrate data from a phase ii study in order to provide a quantitative …